Trial Profile
Pharmacokinetics, Safety and Tolerability of Single Oral Doses (0.1, 0.2, 0.4 and 0.8 mg) of Tamsulosin Hydrochloride in Children With Voiding Disorders
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Oct 2014
Price :
$35
*
At a glance
- Drugs Tamsulosin (Primary)
- Indications Urination disorders
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 22 Oct 2014 New trial record